ValiPharma

ValiPharma is a UK-based biotechnology company and a subsidiary of ValiRx PLC, specializing in the development of novel therapeutics for oncology and women's health. The company's lead programs focus on inhibiting the Src kinase pathway to treat hormone-responsive conditions such as prostate cancer and endometriosis. Their primary candidate, VAL201, is a peptide-based therapy designed to inhibit abnormal cell proliferation without affecting normal reproductive functions. ValiPharma leverages its parent company's resources to advance early-stage assets through clinical proof-of-concept. The company's approach aims to provide targeted treatments with reduced side effects compared to traditional hormone therapies. Currently, ValiPharma is progressing its pipeline through various stages of clinical evaluation.